在紫杉醇、表柔比星和环磷酰胺辅助化疗中加入吉西他滨治疗早期乳腺癌女性(tAnGo):开放标签、随机、3期试验的最终10年随访
tAnGo是一项国际开放标签随机3期优效性试验,纳入3152例早期乳腺癌女性,比较EC-P方案与EC-P联合吉西他滨方案。中位随访10年,10年无病生存率两组均为65%(吉西他滨组65%[63-68] vs 对照组65%[62-67]),调整后风险比0.97(95%CI 0.86-1.10),p=0.64,无显著差异。吉西他滨组3-4级中性粒细胞减少等毒性发生率更高。
要点
- 中位随访10年,吉西他滨组与对照组10年无病生存率均为65%,无显著差异。
- 调整后风险比0.97(95%CI 0.86-1.10),p=0.64,未达统计学显著。
- 吉西他滨组3-4级中性粒细胞减少34% vs 对照组26%,毒性增加。
核心结论
- 在蒽环类和紫杉类辅助化疗中加入吉西他滨(按本试验剂量和方案)在早期乳腺癌中未带来无病生存获益,但可导致毒性增加。
- 因此,吉西他滨未被加入任何亚组乳腺癌的标准辅助化疗。
研究设计与样本
- tAnGo为国际、开放标签、随机、3期优效性试验,纳入18岁及以上新诊断早期乳腺癌女性,来自英国和爱尔兰127个临床中心和医院。
- 患者按1:1随机分配至表柔比星、环磷酰胺和紫杉醇组(对照组)或表柔比星、环磷酰胺和紫杉醇联合吉西他滨组(吉西他滨组),共入组3152例(吉西他滨组n=1576,对照组n=1576)。
- 主要终点为无病生存,试验旨在检测5年无病生存率5%的差异;招募于2004年完成,本次为最终意向性治疗分析。
主要发现
- 中位随访10年(IQR 10-10),发生1087例无病生存事件和914例死亡。
- 10年无病生存率吉西他滨组65%(63-68)vs 对照组65%(62-67),调整后风险比0.97(95%CI 0.86-1.10),p=0.64。
- 3-4级毒性:中性粒细胞减少吉西他滨组527/1565(34%)vs 对照组412/1567(26%),肌痛和关节痛207(13%)vs 186(12%),疲乏207(13%)vs 152(10%),感染202(13%)vs 141(9%),呕吐143(9%)vs 108(7%),恶心132(8%)vs 102(7%)。
关键数值与推荐
- 表柔比星90 mg/m2静脉给药、环磷酰胺600 mg/m2静脉给药,第1天,每3周一次,共4周期;随后紫杉醇175 mg/m2静脉输注3小时,第1天,每3周一次,共4周期。
- 吉西他滨组在紫杉醇周期中加入吉西他滨1250 mg/m2静脉输注0.5小时,第1天和第8天,每3周一次。
- 分层因素包括国家、年龄、放疗意图、淋巴结状态、雌激素受体和HER-2状态。
临床怎么用
- 原文结论指出,吉西他滨未被加入乳腺癌任何亚组的标准辅助化疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel. METHODS: tAnGo was an international, open-label, randomised, phase 3 superiority trial that enrolled women aged 18 years or older with newly diagnosed, early-stage breast cancer who had a definite indication for chemotherapy, any nodal status, any hormone receptor status, Eastern Cooperative Oncology Group performance status of 0-1, and adequate bone marrow, hepatic, and renal function. Women were recruited from 127 clinical centres and hospitals in the UK and Ireland, and randomly assigned (1:1) to one of two treatment regimens: epirubicin, cyclophosphamide, and paclitaxel (four cycles of 90 mg/m2 intravenously administered epirubicin and 600 mg/m2 intravenously administered cyclophosphamide on day 1 every 3 weeks, followed by four cycles of 175 mg/m2 paclitaxel as a 3 h infusion on day 1 every 3 weeks) or epirubicin, cyclophosphamide, and paclitaxel plus gemcitabine (the same chemotherapy regimen as the other group, with the addition of 1250 mg/m2 gemcitabine to the paclitaxel cycles, administered intravenously as a 0·5 h infusion on days 1 and 8 every 3 weeks). Patients were randomly assigned by a central computerised deterministic minimisation procedure, with stratification by country, age, radiotherapy intent, nodal status, and oestrogen receptor and HER-2 status. The primary endpoint was disease-free survival and the trial aimed to detect 5% differences in 5-year disease-free survival between the treatment groups. Recruitment completed in 2004 and this is the final, intention-to-treat analysis. This trial is registered with EudraCT (2004-002927-41), ISRCTN (51146252), and ClinicalTrials.gov (NCT00039546). FINDINGS: Between Aug 22, 2001, and Nov 26, 2004, 3152 patients were enrolled and randomly assigned to epirubicin, cyclophosphamide, paclitaxel, and gemcitabine (gemcitabine group; n=1576) or to epirubicin, cyclophosphamide, and paclitaxel (control group; n=1576). 11 patients (six in the gemcitabine group and five in the control group) were ineligible because of pre-existing metastases and were therefore excluded from the analysis. At this protocol-specified final analysis (median follow-up 10 years [IQR 10-10]), 1087 disease-free survival events and 914 deaths had occurred. Disease-free survival did not differ significantly between the treatment groups at 10 years (65% [63-68] in the gemcitabine group vs 65% [62-67] in the control group), and median disease-free survival was not reached (adjusted hazard ratio 0·97 [95% CI 0·86-1·10], p=0·64). Toxicity, dose intensity, and a detailed safety substudy showed both regimens to be safe, deliverable, and tolerable. Grade 3 and 4 toxicities were reported at expected levels in both groups. The most common were neutropenia (527 [34%] of 1565 patients in the gemcitabine group vs 412 [26%] of 1567 in the control group), myalgia and arthralgia (207 [13%] vs 186 [12%]), fatigue (207 [13%] vs 152 [10%]), infection (202 [13%] vs 141 [9%]), vomiting (143 [9%] vs 108 [7%]), and nausea (132 [8%] vs 102 [7%]). INTERPRETATION: The addition of gemcitabine to anthracycline and taxane-based adjuvant chemotherapy at this dose and schedule confers no therapeutic advantage in terms of disease-free survival in early breast cancer, although it can cause increased toxicity. Therefore, gemcitabine has not been added to standard adjuvant chemotherapy in breast cancer for any subgroup. FUNDING: Cancer Research UK core funding for Clinical Trials Unit at the University of Birmingham, Eli Lilly, Bristol-Myers Squibb, and Pfizer.
引用
- Earl HM, Hiller L, Howard HC, et al. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017. PMID: 28479233. doi:10.1016/S1470-2045(17)30319-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。